Recent News for CNAT - Conatus Pharmaceuticals Inc.

Date Title
Aug 19 Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know
Aug 7 Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies
Aug 6 Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates
Aug 6 Conatus Pharmaceuticals beats on revenue
Aug 6 Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates
Aug 3 The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts
Aug 3 29 Healthcare Stocks Moving In Friday's After-Market Session
Jul 31 Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know
Jul 27 The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Jul 26 30 Healthcare Stocks Moving In Thursday's After-Market Session
Jul 25 Investors Who Bought Conatus Pharmaceuticals (NASDAQ:CNAT) Shares Five Years Ago Are Now Down 96%
Jun 26 Conatus (CNAT) Stock Price Could Hit Zero
Jun 26 Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
Jun 26 The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
Jun 26 Conatus' Emricasan Lags Primary Goal in Liver Function Study
Jun 25 Mid-Afternoon Market Update: NASDAQ Down 1.5%; Acer Therapeutics Shares Slide
Jun 25 Mid-Day Market Update: Allergan Jumps On Acquisition News; Conatus Pharmaceuticals Shares Plunge
Jun 25 NASH Disappointment Forces Conatus To Explore Strategic Alternatives
Jun 25 The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership
Jun 24 UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial
Jun 24 Conatus to explore strategic alternatives
Jun 24 Conatus to Explore Strategic Alternatives and Implement Restructuring Plan
Jun 24 Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis
Jun 12 CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
Jun 1 Conatus (CNAT) Down 5.8% Since Last Earnings Report: Can It Rebound?
Back to the Main CNAT Page...